Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
Source: SeekingAlpha
2026-04-25 04:27:34 ET
...
Read the full article on Seeking Alpha
For further details see:
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
Oncolytics Biotech Inc.
NASDAQ: ONCY
ONCY Trading
6.76% G/L:
$1.105 Last:
5,276,502 Volume:
$1.14 Open:
ONCY Latest News
June 01, 2026 09:00:00 am
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
May 26, 2026 09:00:00 am
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
ONCY Stock Data
$91,131,840
106,702,482
13.96%
27
N/A
Biotechnology & Life Sciences
Healthcare
CA
San Diego
